Document is current
Any future updates will be listed below
-
Authors
van der Meel, Roy https://orcid.org/0000-0002-2200-7946
Wender, Paul A.
Merkel, Olivia M.
Lostalé-Seijo, Irene
Montenegro, Javier
Miserez, Ali https://orcid.org/0000-0003-0864-8170
Laurent, Quentin
Sleiman, Hanadi https://orcid.org/0000-0002-5100-0532
Luciani, Paola
- License Information
-
More Information
Article History
Accepted: 14 May 2025
First Online: 16 June 2025
Competing interests
: R.v.d.M. is listed as inventor on patent applications WO2022268913A1, WO2023233042A1, WO2023227682A1 and WO2023046931A1, related to apolipoprotein nanoparticle technology. P.A.W. is a co-inventor on several patents and patent applications filed by Stanford University related to the discussed topic (12215341, 20240277854, 20240277870, 20240148858, 11931416, 20220143199, 20220088163, 10961263, 20200308200, 10654875, 20180319825 and 20180028688) and is a co-founder of N1 Life, a delivery company. O.M.M. is a co-founder of RNhale GmbH, a Scientific Board Member for Coriolis Pharma GmbH, AMW GmbH, and Corden Pharma International GmbH, and an Advisor for PARI Pharma GmbH, Boehringer-Ingelheim International GmbH, and AbbVie Deutschland GmbH & Co. KG on unrelated projects. None of these companies were involved in or funded the research presented here. J.M. and I.L.-S. are listed as inventors on a patent application (WO2023247781A1) related to peptide amphiphiles. P.L. is a board member of the Center for Extracellular Vesicle Research (EVR) of the University of Bern; has consulted and received research grants from Lipoid GmbH, Sanofi-Aventis Deutschland and DSM Nutritional Products Ltd on unrelated projects; and has received research grants from PPM Services S.A on unrelated projects. The other authors declare no competing interests.
